Detalles de la búsqueda
1.
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Mod Pathol;
25(6): 902-10, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22460813
2.
The CT flare response of metastatic bone disease in prostate cancer.
Acta Radiol;
52(5): 557-61, 2011 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21498309
3.
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Cancers (Basel);
13(10)2021 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34066080
4.
A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies.
Prostate;
69(14): 1507-20, 2009 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19544327
5.
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
J Clin Endocrinol Metab;
97(2): 507-16, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22170708
6.
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
J Clin Oncol;
28(9): 1489-95, 2010 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-20159823
7.
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
Cancer Res;
69(12): 4937-40, 2009 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19509232
8.
Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
Clin Cancer Res;
15(15): 4799-805, 2009 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19638457
9.
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.
Clin Cancer Res;
15(15): 4978-85, 2009 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19638462
10.
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
J Clin Oncol;
27(23): 3742-8, 2009 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19470933
11.
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Cancer Res;
69(7): 2912-8, 2009 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19339269
12.
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
J Clin Oncol;
26(28): 4563-71, 2008 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18645193
13.
Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
J Clin Oncol;
28(29): e560-1; author reply e562, 2010 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20805462
Resultados
1 -
13
de 13
1
Próxima >
>>